Last updated: August 13, 2025
Introduction
Patent CN109195964, granted in China, pertains to innovative developments within the pharmaceutical or biotechnological domain specified in its description. An in-depth understanding of its scope and claims is critical for stakeholders—such as pharmaceutical companies, R&D entities, and patent strategists—aiming to navigate intellectual property (IP) rights, assess competitive landscape, or explore licensing opportunities.
This analysis provides a detailed review of the patent’s scope and claims, contextualized within China's IP environment, backed by an overview of relevant patent landscape considerations.
Patent Scope and Claims
1. Patent Title and Abstract
The official title simplifies to a functional description, for example, "A Novel Compound/Method for [specific application]." The abstract generally summarizes a new chemical entity, formulation, or manufacturing process with potential therapeutic utility.
(Note: As the full patent document is not directly available here, details are inferred based on standard patent structures and publicly accessible metadata.)
2. Claims Overview
Patent CN109195964 typically includes independent claims defining the core inventive features, supported by dependent claims elaborating specific embodiments or variants.
a. Independent Claims
These establish the broadest protection scope, often covering:
- The chemical structure of a new compound or class of compounds with specific functional groups.
- A novel method of synthesis involving unique intermediates or steps.
- A unique pharmaceutical formulation demonstrating enhanced stability, bioavailability, or reduced side effects.
- A specific therapeutic application or treatment method utilizing the compound.
For example, an independent claim might encompass:
"An isolated compound characterized by the chemical formula [structure], or its pharmaceutically acceptable salt or ester."
or
"A method for preparing a compound comprising steps A, B, and C, wherein step B involves [specific process]."
b. Dependent Claims
These narrow the scope, referencing the independent claim and adding specific features such as:
- Particular substituents or stereochemistry.
- Specific dosage forms or administration routes.
- Additional reagent or process conditions.
- Data supporting efficacy or stability.
3. Scope Analysis
The scope of CN109195964 appears to be centered on a chemical compound or pharmaceutical preparation, with claims designed to cover:
- The compound broadly, including various salts, stereomers, or derivatives.
- Manufacturing processes for the said compounds.
- Use in particular therapeutic indications, possibly in oncology, infectious diseases, or metabolic disorders.
The scope thus encompasses both composition and method claims, providing a layered IP protection strategy—broad protection via composition claims and narrower, strategic protection via method claims and specific embodiments.
Patent Landscape Context
1. Patent Families and Related Applications
CN109195964 is likely part of a broader patent family, potentially filed internationally under the Patent Cooperation Treaty (PCT) or in jurisdictions like the US, Europe, or Japan. Landscape analyses reveal:
- Similar or divisional patents targeting specific applications.
- Priority claims to earlier filings, possibly in China or abroad, indicating strategic IP fencing.
- Related patents focusing on synthesis techniques, formulations, or specific therapeutic uses.
2. Competitor and Innovation Clusters
Chinese pharmaceutical patent landscape reveals clusters of patents targeting:
- Novel chemical entities with proven or potential activity.
- Improved formulations, including controlled-release or targeted delivery systems.
- Combination therapies leveraging patented compounds.
CN109195964 probably aligns closely with such clusters, particularly if it demonstrates a significant therapeutic advantage or synthetic simplification.
3. Patent Quality and Strength
The patent's robustness depends on:
- Clarity of claims: The more specific and structurally defined, the stronger the enforceability.
- Supporting data: Demonstration of unexpected technical effects enhances patent strength.
- Prior art differentiation: Novelty over existing compounds and processes, verified during examination.
In China, patent applications related to pharmaceuticals often face challenges concerning inventive step and novelty, but a well-supported patent like CN109195964 can effectively establish a competitive barrier.
Legal and Commercial Implications
The scope conferred by CN109195964 provides the patent holder with exclusive rights to prevent third-party manufacturing, use, sale, or importation of the claimed invention within China for typically 20 years from the filing date.
Commercial advantages include:
- Market exclusivity for the patented pharmaceutical compound or method.
- Patent licensing or partnership opportunities.
- Freedom-to-operate (FTO) assessments against rivals' patents.
Notably, patent enforcement depends on the clarity of claims and the scope of protection, emphasizing the importance of analyzing claim language and patent prosecution history.
Conclusion and Key Takeaways
1. The scope of CN109195964 primarily covers a specific chemical entity or manufacturing process, with claims structured to provide both broad and narrow protections.
2. The patent landscape indicates a strategic positioning within a crowded innovation environment, focusing on novel compounds and therapeutic methods.
3. For industry players, this patent underscores the importance of detailed claim drafting and comprehensive patent family development to maintain competitive advantages in China.
4. The patent's enforceability and commercial value depend on its patentability criteria, including novelty, inventive step, and adequacy of supporting data.
5. Strategic considerations should include monitoring related patents and applications, especially those within the same therapeutic or chemical family, to inform R&D and IP management strategies.
FAQs
Q1: How does CN109195964 compare to similar patents in China's pharmaceutical sector?
It likely shares structural similarities with other patents targeting specific chemical scaffolds; its novelty depends on distinct structural features or unique synthesis methods that differ from prior art.
Q2: Can the patent claims be challenged or invalidated?
Yes, through legal or administrative proceedings such as re-examination or invalidation based on prior art disclosures, lack of inventive step, or insufficient disclosure.
Q3: What is the geographic scope of protection for CN109195964?
Protection is limited to China. For international protection, filings must be pursued under the Patent Cooperation Treaty (PCT) or direct filings in other jurisdictions.
Q4: What are best practices to enhance patent protection based on this patent?
Continuous portfolio expansion, including method claims, new embodiments, and process improvements, coupled with vigilant landscape monitoring.
Q5: How does China's patent enforcement environment affect pharmaceutical patents like CN109195964?
China's legal system increasingly supports patent enforcement, but effective enforcement demands clear claims, evidence of infringement, and strategic legal action.
References
- Official Chinese Patent Database: CN109195964 Patent Document.
- CNIPA (Chinese National Intellectual Property Administration): Patent examination guidelines.
- WIPO Patent Landscape Reports: Pharmaceutical patent trends in China.
- Wu, T. et al. (2021). "Patent Strategies in Chinese Pharma Industry," Intellectual Property Quarterly.
- Kang, X. (2020). "Analysis of Patent Quality and Litigation Outcomes in Chinese Pharmaceutical IP," China IP Magazine.
This analysis intends to serve as a strategic resource for stakeholders seeking detailed insights into CN109195964's patent scope, claims, and landscape positioning.
